BioSpace News Archive

AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases and WuXi Biologics (2269.HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, today announced the first steps of an exclusive strategic collaboration that covers biologics discovery, development and manufacturing.

MilliporeSigma today announced it has extended and expanded its collaboration with Kuraray Europe to exclusively supply pharmaceutical polyvinyl alcohol (PVA) grades and improvements to benefit the pharmaceutical market.

pMD, recently made enhancements to its free, secure messaging product.

[19-December-2018] PHILADELPHIA , Dec. 19, 2018 /PRNewswire/ -- The National Board of Osteopathic Medical Examiners (NBOME) Board is pleased to introduce four new directors recently elected to the NBOME Board. Robert J. Corona, Jr. , DO, MBA , of New York State , is a nationally recognized leader and advocate for transforming medical education, acade

ILiAD Biotechnologies, LLC, announced the initial closing of a Class C financing, which will provide ILiAD with up to $20 million of proceeds

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA, today reported financial results and business highlights for the fiscal 2018 fourth quarter and full year ended September 30, 2018.

TCR2 Therapeutics Inc., an innovative immunotherapy company developing the next generation of novel T cell receptor (TCR) therapies for patients suffering from cancer, today announced the appointment of Andrew Allen, M.D., Ph.D. to its Board of Directors

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA, Merck’s anti-PD-1 therapy, for the treatment of adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC), based on the results of the Cancer Immunotherapy Trials Network (CITN)’s CITN-09/KEYNOTE-017 trial.

New Rhein Healthcare Investors, an international private equity firm focused on healthcare therapeutics and medical devices, announced today the first closing of its inaugural pooled fund.

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Teladoc Health, Inc. (“Teladoc” or the “Company”) (NYSE:TDOC) of the February 11, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.